Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
NCT05728736 · Brendan Lucey · PHASE2 · withdrawn · last registry update 2023-11-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated due to enrollment difficulties and the inability to obtain necessary study supplies. Five participants signed consent; however, no one was randomized. The study was officially terminated with the funding source on 10/04/2023.” | – | Registry record, Brendan Lucey |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HCRTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-24Phase 3 first posted: Merck Sharp & Dohme LLC, Suvorexant + Placebo (NCT06655883)
- 2024-09-25Also stopped (terminated): Wayne State University, Suvorexant + Suvorexant Placebo (NCT04262193)
- 2024-08-20Results posted on the registry: Burdick, Daniel, M.D., Suvorexant + Placebo (NCT02729714)
- 2024-07-11Phase 3 first posted: Phramongkutklao College of Medicine and Hospital, Lemborexant + Placebo (NCT06496282)
- 2024-05-20Results posted on the registry: Merck Sharp & Dohme LLC, Suvorexant + Placebo (NCT04571944)
- 2024-02-16Phase 3 first posted: University of Manitoba, Lemborexant + Placebo (NCT06262594)
- 2024-02-12Results posted on the registry: Milton S. Hershey Medical Center, Suvorexant 20 mg (NCT03412591)
- 2024-01-16Results posted on the registry: Massachusetts General Hospital, Suvorexant (NCT04706091)
- 2023-10-10Results posted on the registry: Eisai Inc., Placebo + Lemborexant 10 mg (NCT04647383)
- 2023-08-24Phase 3 first posted: Jiangsu Simcere Pharmaceutical Co., Ltd., Daridorexant + Placebo (NCT06010693)
- 2023-06-02Results posted on the registry: Howard University, suvorexant (NCT02849548)
- 2023-04-26Results posted on the registry: The Scripps Research Institute, Suvorexant 20 mg + Placebo oral tablet (NCT04229095)
- 2023-03-02Results posted on the registry: Massachusetts General Hospital, Suvorexant (NCT03818581)
- 2023-02-15Also stopped (terminated): The Florey Institute of Neuroscience and Mental Health, Suvorexant 20 mg (NCT03897062)
- 2023-02-15Results posted on the registry: Howard University, suvorexant (NCT02704754)
- 2023-02-08Results posted on the registry: William Stoops, Suvorexant + Cocaine (NCT03937986)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision